Controlling eosinophils

I vividly recall the excitement on the faces of thousands of physicians attending the AAAAI meeting back in 1986 where for the first time the significance of IL5 was being introduced to the allergy arena. Now we are using Nucala: mepolizumab; anti-interleukin [IL]-5 on select patients. New biologicals are the key to success

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s